Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C1 | P04150 | 13/20 | 0.39 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.37 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29825100 | 0.85 | DGAT1 (0.39) | NR3C1ADORA1ADORA2AALDH1A1KDM4E | |
| SCHEMBL21772867 | 0.85 | DGAT1 (0.39) | NR3C1ADORA1ADORA2AALDH1A1KDM4E | |
| SCHEMBL25239987 | 0.83 | NR3C1 (0.42) | NR3C1 | |
| SCHEMBL31140751 | 0.83 | NR3C1 (0.42) | NR3C1 | |
| SCHEMBL17546011 | 0.81 | MGLL (0.44) | NR3C1ALDH1A1KDM4E | |
| SCHEMBL23885083 | 0.81 | FPR2 (0.43) | NR3C1ADORA1ADORA2AALDH1A1KDM4E | |
| SCHEMBL21788991 | 0.80 | ALDH1A1 (0.39) | NR3C1ADORA1ADORA2AALDH1A1KMT2A | |
| SCHEMBL12644155 | 0.75 | NR3C1 (0.36) | NR3C1ADORA1ADORA2AALDH1A1KMT2A | |
| SCHEMBL30807913 | 0.74 | KMT2A (0.45) | ALDH1A1KMT2AKDM4EMEN1 | |
| SCHEMBL566860 | 0.74 | KMT2A (0.45) | ALDH1A1KMT2AKDM4EMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200071326-A1 | TAM KINASE INHIBITORS | SYROS PHARMACEUTICALS INC (US) | 2020-03-05 | — | — | US | disclosed |
| US-20200071326-A1 | TAM KINASE INHIBITORS | SYROS PHARMACEUTICALS INC (US) | 2020-03-05 | — | — | US | disclosed |
| WO-2018191587-A1 | TAM KINASE INHIBITORS | SYROS PHARMACEUTICALS, INC. (US) | 2018-10-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200071326-A1 | TAM KINASE INHIBITORS | PIK3CA, MAP3K1, MAP3K5 | NR3C1 2396/4885ADORA1 1072/4885ADORA2A 792/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.